Welcome to our dedicated page for Telix Pharmaceuticals SEC filings (Ticker: TLPPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telix Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telix Pharmaceuticals's regulatory disclosures and financial reporting.
Telix Pharmaceuticals Ltd (TLX) reports completion of patient enrollment in its Phase 3 BiPASS study, evaluating Illuccix and Gozellix 68Ga‑PSMA‑PET imaging combined with MRI for prostate cancer diagnosis in the pre‑biopsy setting. The prospective, open‑label trial enrolled 350 patients in the U.S. and Australia. Telix has also aligned with the U.S. FDA on a New Drug Application (NDA) pathway for BiPASS that, if approved, could support reimbursement as a new product and broaden patient access to gallium‑based PSMA‑PET imaging. BiPASS builds on PRIMARY and PRIMARY2 data showing that adding 68Ga‑PSMA‑PET to MRI can significantly improve detection of clinically significant prostate cancer while reducing unnecessary biopsies by almost 50 percent, with the potential to shift PSMA‑PET into an earlier, diagnostic role.
Telix Pharmaceuticals Limited (TLX) has appointed David Gill as Chair of the Board, effective immediately, as disclosed in a September 1, 2026 announcement. Gill joined the Board as a Non-Executive Director in May 2026 as part of Telix’s Board expansion and succession planning. He succeeds interim Chair Dr. Mark Nelson, who will remain on the Board as a Non-Executive Director.
Gill is a life sciences executive with over 35 years of senior management and financial leadership experience across biopharmaceutical and medical device companies, including radiopharmaceutical development, manufacturing and supply chain. Telix describes his expertise in capital markets, business scaling, governance and corporate turnaround strategy as important as the company continues to grow its global radiopharmaceutical theranostics franchise and late-stage oncology pipeline.
Telix Pharmaceuticals Limited (TLX) reported strong H1 2026 results, with revenue from contracts with customers of $477.3M, up 22% from $390.4M a year earlier, driven mainly by Illuccix and Gozellix in its Precision Medicine segment and contributions from RLS within Manufacturing Solutions.
Gross profit rose to $260.3M with the group gross margin improving to 55%, while Precision Medicine gross margin reached 65%. R&D spending increased 52% to $123.8M as Telix advanced multiple late-stage therapeutic programs and regulatory filings. The company recorded an operating profit of $46.4M and net profit after tax of $38.3M, compared with a prior-period loss of $2.3M, supported by a $40.0M upfront payment from a new collaboration with Regeneron.
Adjusted EBITDA increased to $51.9M from $21.1M, and cash and cash equivalents rose to $251.9M from $141.9M at December 31, 2025, helped by issuance of $600M 1.50% Convertible Notes due 2031 and the refinancing of prior 2029 bonds. Telix reaffirmed FY 2026 revenue guidance of $950–$970M, expecting results toward the upper end.
Telix Pharmaceuticals Limited reports Q2 2026 group revenue of US$247 million, up 21% year-over-year and 7% quarter-over-quarter. Precision Medicine revenue was US$202 million, up 30% year-over-year and 9% quarter-over-quarter, while Telix Manufacturing Solutions contributed US$45 million.
For FY 2026, Telix expects revenue and other income to exceed US$1 billion, with revenue tracking toward the upper end of its US$950–US$970 million range, plus US$40 million in non-refundable income from a strategic collaboration with Regeneron. R&D spending guidance is increased to US$230–US$270 million to accelerate late-stage programs, including TLX597-Tx and Pixclara label expansion.
The Therapeutics pipeline advanced with FDA alignment to move TLX591-Tx’s ProstACT Global Phase 3 study to Part 2 in the U.S., first patients dosed in pivotal trials for TLX250-Tx (kidney cancer) and TLX101-Tx (glioblastoma), and strong enrollment across multiple studies. In Precision Medicine, Telix rapidly enrolled 338 patients in the BiPASS Phase 3 prostate cancer study, progressed Japanese and U.S. regulatory paths for Illuccix, Pixclara and Zircaix, and expanded manufacturing capacity in Australia, Belgium and Japan. Telix also entered a Regeneron collaboration, received US$40 million upfront, refinanced with US$600 million of 2031 convertible bonds, and appointed three new Non-Executive Directors.
Telix Pharmaceuticals reports alignment with the U.S. FDA to advance Part 2 of its ProstACT Global Phase 3 trial of TLX591-Tx in metastatic castration-resistant prostate cancer. The FDA confirmed that Part 1 safety data are sufficient to enable progression of Part 2 in the U.S. and agreed with the clinical protocol, statistical analysis plan and ongoing safety monitoring.
In Part 2, TLX591-Tx is given in two doses 14 days apart alongside one of three standard-of-care therapies: abiraterone, enzalutamide or docetaxel, under a randomized design. The trial’s safety and dosimetry lead-in (Part 1) enrolled 36 patients and is complete, and the global expansion (Part 2) targets approximately 490 patients. Enrollment continues in multiple countries, while U.S. initiation remains subject to FDA review of an Investigational New Drug amendment. Telix highlights TLX591-Tx as part of a broader radiopharmaceutical pipeline spanning prostate, brain and kidney cancers.
Telix Pharmaceuticals Limited submitted a Form 6-K as a foreign private issuer, forwarding materials from its Annual General Meeting held in May 2026. The filing makes available the Chairman and CEO addresses, an AGM presentation, and the results of the AGM as exhibits for U.S. investors.
Telix Pharmaceuticals Ltd filed an initial Form 3 identifying David N. Gill as a director of the company. The filing’s transaction summary shows no reported purchases, sales, exercises, gifts, or other share movements, and net buy/sell activity is neutral in this excerpt.
Telix Pharmaceuticals Ltd filed an initial Form 3 for board member Maria Rivas. This filing establishes her status as a director and provides a baseline disclosure of her beneficial ownership as an insider. The data provided shows no reported purchases, sales, exercises, gifts, or other equity transactions.
Telix Pharmaceuticals Ltd MD & Group CEO Dr. Christian Behrenbruch, through Elk River Holdings Pty Ltd, made two open-market purchases of Ordinary Shares. On April 28 and 29, he indirectly bought a combined 67,935 shares at average prices around $14.48 and $14.87 per share, reported in Australian Dollars. After these transactions, his indirect holdings rose to 20,742,935 Ordinary Shares. The filing notes that the reported prices are volume-weighted averages for multiple trades within specified price ranges.
Telix Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K relating to its shareholder meeting materials. On April 21, 2026 in Melbourne, the company lodged with the Australian Securities Exchange an announcement titled “Telix Notice of AGM, Proxy Form and Online Guide,” which is furnished to U.S. investors as Exhibit 99.1.